DVA · NYSE
DaVita Inc.
$185.38 +1.74 (+0.95%)
Company overview
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and provides management and administrative services to outpatient dialysis centers. In addition, the company offers disease management services, vascular access services, clinical research programs, physician services, and comprehensive kidney care services.
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Exchange
- NYSE
- Market cap
- $11.8B
- Employees
- 76,000
- Headquarters
- Denver, CO
- Website
- davita.com
- CEO
- Javier J. Rodriguez
- Listed
- October 31, 1995
- P/E
- 18.26
- Dividend yield
- 0.00%
Company financials
- Revenue
- $13.8B
- Gross profit
- $4.3B
- Operating income
- $2.1B
- EBITDA
- $2.7B
- Net income
- $781M
- EPS
- $10.15
- Total assets
- $17.5B
- Total debt
- $13.2B
- Gross margin
- 31.10%
- Net margin
- 5.65%
- Earnings yield
- 5.48%
No geographic segmentation.
Showing FY 2025
DVA
1D
NYSE
O184.52H187.52L183.46C183.64-2.46 (-1.32%)Vol618.10K